fda compounding semaglutide warning november 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots What Patients Need to Know

Patients taking a GLP-1 need to be supported by multidisciplinary care teams that practice strong patient education strategies

Using IU Markings with U100 Insulin Syringes Many users rely on U100 insulin syringes with IU (insulin unit) markings

Additionally, semaglutide should not be used concurrently with other GLP-1 receptor agonists

Larger amounts of semaglutide will produce greater health benefits but may cause more severe side effects, such as hypoglycemia or gastrointestinal issues in some cases

In clinical trials, there were no severe adverse events

With the popularity of GLP-1 agonists ever-increasing and over 150 GLP-1 drug candidates in development [3], the field is continually expanding, most recently into oncology and obesity-related cancers.[4] While most approved GLP-1RAs require subcutaneous injection, substantial work is being undertaken to move toward oral GLP-1 therapies [5], such as Rybelsus which was the first oral GLP-1RA approved by the FDA in 2019